The GLP1-RA and most recently tirzepatide, a dual agonist of GLP1 and GIP, have shown a very important effect on weight reduction (in order of 10-15%) and therefore may consider potentially agents with a great capacity for diabetes remission in a less aggressive way than surgery, early intensive insulin therapy and VLCD (33, 34). Here, INS is linked to diabetes mellitus.